NanoART, neuroAIDS and CNS drug delivery.
NanoART, neuroAIDS and CNS drug delivery.
复制标题
DOI：
10.2217/nnm.09.38
复制
发表时间：
2009-07
期刊：
影响因子：
--
通讯作者：
Gendelman HE
中科院分区：
文献类型：
--
作者：
Nowacek A;Gendelman HE
正在开发广泛的纳米药物以改善CNS疾病的药物递送。血脑屏障（BBB）的结构，外排泵的存在和代谢酶的表达构成了药物进入脑的障碍。纳米制剂可以绕过血脑屏障，通过影响这些泵和酶来改善CNS导向的药物递送。或者，它们可以被优化以影响它们的大小、形状以及蛋白质和脂质涂层，以促进药物吸收、释放和穿过屏障进入。这一点很重要，因为大脑是包括HIV-1在内的多种病原体的避难所。改善药物向CNS的递送将影响药代动力学和药物生物分布特性。本文重点介绍纳米技术如何有助于改善抗逆转录病毒药物（称为nanoART）在BBB中的传递，并影响HIV-1疾病的生物分布和临床获益。
A broad range of nanomedicines is being developed to improve drug delivery for CNS disorders. The structure of the blood–brain barrier (BBB), the presence of efflux pumps and the expression of metabolic enzymes pose hurdles for drug-brain entry. Nanoformulations can circumvent the BBB to improve CNS-directed drug delivery by affecting such pumps and enzymes. Alternatively, they can be optimized to affect their size, shape, and protein and lipid coatings to facilitate drug uptake, release and ingress across the barrier. This is important as the brain is a sanctuary for a broad range of pathogens including HIV-1. Improved drug delivery to the CNS would affect pharmacokinetic and drug biodistribution properties. This article focuses on how nanotechnology can serve to improve the delivery of antiretroviral medicines, termed nanoART, across the BBB and affect the biodistribution and clinical benefit for HIV-1 disease.